US NIH funds Israeli radiation therapy

The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see here) as a treatment for Hematopoietic Acute Radiation Syndrome – a deadly disease that can result from nuclear disasters and radiation exposure.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *